We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Cristina Roca
Roche Holding AG (RO.EB) said Monday that it has struck a licensing deal with Sarepta Therapeutics Inc. (SRPT) for the exclusive right to launch and commercialize a gene therapy used for patients with Duchenne muscular dystrophy outside the U.S.
The Swiss pharmaceutical company said it will pay Sarepta an upfront $750 million in cash and $400 million in equity at closing, which is expected in the first quarter of 2020, for the rights to its SRP-9001 investigational gene therapy.
Sarepta is also eligible to receive regulatory and sales milestones of up to $1.7 billion, plus royalties on net sales, Roche said. The two companies will also share global development expenses.
Write to Cristina Roca at cristina.roca@dowjones.com
(END) Dow Jones Newswires
December 23, 2019 02:10 ET (07:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
